Follow-The-Filings

Security

Spyre Therapeutics Inc. · COM NEW

Equity holders as of 2026 Q1 (each manager’s latest book)

6 owners 1 new 1 exit max 0.0% (Marshall Wace - Marshall ...)

owners 6
max % 0.0%
tracked value $156M
qoq N 1 A 4 R 1 E 1

holders

sorted by % of portfolio · long equity only · exits show last held size

manager % port activity shares value history
Marshall Wace - Marshall Wace, LLP 2026 Q1 0.0% New 0.0% 139,259 $7M hist
Vanguard Group Inc. 2025 Q4 stale 0.0% Add 0.00 pp 4,035,074 $132M hist
Israel Englander - Millennium Management LLC 2026 Q1 0.0% Add 0.00 pp 146,639 $7M hist
Ken Griffin - Citadel Advisors LLC 2026 Q1 0.0% Add 0.00 pp 108,135 $5M hist
Dmitry Balyasny - Balyasny Asset Management L.P. 2026 Q1 0.0% Reduce 0.00 pp 55,477 $3M hist
Cliff Asness - Aqr Capital Management LLC 2026 Q1 0.0% Add 0.00 pp 20,874 $1M hist
Steve Cohen - Point72 Asset Management, L.P. exited 2026 Q1 last 2025 Q4 0.0% Exit -0.02 pp 662,351 $22M hist

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $886,000 $0.00 $0.00
Gross profit
Gross margin
Net income -$338.79M -$208.02M -$155.2M
Net margin * -38238.1%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $341.53M $608.47M $777.78M
Total non-current assets * $331,000 $10,000 $0.00
Total assets $341.86M $608.48M $777.78M
Total current liabilities $31.98M $54.06M $58.68M
Total non-current liabilities * $41.31M $36.62M $3.86M
Total equity $184.02M $517.8M $715.24M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$99.91M -$157.41M -$169.25M
Cash from investing -$108.39M -$353.28M -$143.48M
Cash from financing $361.08M $410.91M $309.02M
Net change in cash $152.8M -$99.79M -$3.7M

ownership over time

filing count by report period · click a bar for that quarter’s holders